-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Merck & Co.
Pneumococcal disease is a disease caused by Streptococcus pneumoniae infection.
Vaxneuvance is a 15-valent pneumococcal conjugate vaccine consisting of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F bound to the CRM197 carrier protein And 33F purified capsular polysaccharide composition
This application is based on positive data obtained from phase 2 and phase 3 clinical trials of the vaccine in pediatric populations (including infants, children, and adolescents)
These studies support the potential use of Vaxneuvance in a variety of clinical settings, including immunization for infants and young children, and special populations at increased risk of pneumococcal disease, such as children with HIV infection or sickle cell anemia
Reference materials:
[1] US FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck's Vaxneuvance™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children.
(The original text has been deleted)